Humanigen (HGENQ) Osake Kurssi
Humanigen Kurssi
Liikevaihto on kasvanut 11,8 % vuodessa viimeisten 13 vuoden aikana 2,51 M USD:een. Humanigenn nettomarginaali on nyt −2 817,9 %, laskenut −385,4 %:sta muutama vuosi sitten.
Humanigen osakekurssi
Humanigen liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Humanigen -osakkeesta
The main competitors of Humanigen Inc in the market include pharmaceutical companies such as Eli Lilly and Company, Gilead Sciences Inc, and Regeneron Pharmaceuticals Inc.
Humanigen Inc is a biopharmaceutical company with a focus on advancing transformative monoclonal antibody therapeutics. Their business model revolves around developing and commercializing cutting-edge treatments to address unmet medical needs. Humanigen Inc utilizes its proprietary Humaneered® technology platform to create novel antibodies that target and neutralize disease-causing mechanisms in various diseases such as cancer and infectious diseases. Through strategic partnerships and collaborations, Humanigen Inc aims to bring innovative therapies to patients and improve their quality of life.
Humanigen Inc is primarily active in the biotechnology industry.
Humanigen Inc is a biopharmaceutical company specializing in developing and commercializing cutting-edge immunotherapies for various challenging diseases. Founded in 1997, Humanigen has a rich history in researching innovative treatments, including its proprietary Humaneered® antibody technology platform. With a focus on providing life-changing therapies, Humanigen strives to improve patient outcomes and enhance the quality of life for individuals worldwide. The company's dedication to advancing science and delivering effective solutions has positioned Humanigen as a leader in the biopharmaceutical industry.
Humanigen Inc has achieved several significant milestones. One notable accomplishment is the development of their lead product candidate, lenzilumab. This innovative monoclonal antibody has shown promise in treating various diseases, including COVID-19 and CAR-T therapy-related side effects. Humanigen Inc has also made progress in advancing clinical trials for lenzilumab, with positive results demonstrating its potential efficacy. Furthermore, the company has secured partnerships and collaborations to further enhance their research and development efforts. These milestones highlight Humanigen Inc's commitment to driving advancements in healthcare and their dedication to improving patient outcomes.
Humanigen Inc is primarily present in the United States.
Humanigen Inc represents values of innovation, dedication, and patient-centered care. As a biopharmaceutical company, Humanigen is committed to developing cutting-edge therapies to address unmet medical needs. With a focus on precision medicine and next-generation solutions, the company aims to improve the lives of patients worldwide. Humanigen Inc's corporate philosophy is centered around scientific excellence, ethical conduct, and a mission-driven approach to transform healthcare. By leveraging its expertise and collaborative partnerships, Humanigen strives to offer effective and accessible treatments to patients while ensuring the highest standards of quality and safety.
8 analyytikkoa arvioi tällä hetkellä Humanigen-osaketta: 0 suosittaa ostoa, 3 pitoa ja 5 myyntiä.
Humanigen-osake (HGENQ) on listattuna 4 pörssissä, muun muassa: NASDAQ (HGEN), Frankfurt (0KB2.F), München (0KB2.MU), Düsseldorf (0KB2.DU).
The company Humanigen Inc. is a biopharmaceutical company specializing in the development and marketing of treatments for rare and serious diseases. Its business model includes various sectors, including research and development, manufacturing and marketing of drugs, as well as research in collaboration with academic and nonprofit institutions.
Liikevaihtoa ei voida laskea Humanigen:lle tällä hetkellä.
Voittoa ei voida laskea Humanigen:lle tällä hetkellä.
P/E-suhdetta ei voida laskea Humanigen:lle tällä hetkellä.
P/S-suhdetta ei voida laskea Humanigen:lle tällä hetkellä.
Humanigen:n Eulpool-laatuscore on 3/10.
Humanigen:n ISIN on US4448632038. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Humanigen:n WKN on A2QEQW. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Humanigen:n ticker on HGENQ. Tämä pörssinoteeraus käytetään Humanigen-osakkeiden kauppaan pörssissä.
Humanigen osake
Humanigen vertaisryhmä
Humanigen Ticker
Humanigen FIGI
Kaikki tunnusluvut ja syvällinen analyysi Humanigen:sta
Meidän osakeanalyysimme Humanigen-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Humanigen:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: